Department of Genomic Medicine, Houston, Texas, USA.
Department of Infectious Disease, Infection Control, and Employee Health, Houston, Texas, USA.
Clin Infect Dis. 2020 Jun 24;71(1):63-71. doi: 10.1093/cid/ciz777.
The majority of studies that provide insights into the influence of the microbiome on the health of hematologic malignancy patients have concentrated on the transplant setting. Here, we sought to assess the predictive capacity of the gastrointestinal microbiome and its relationship to infectious outcomes in patients with acute myeloid leukemia (AML).
16s rRNA-based analysis was performed on oral swabs and stool samples obtained biweekly from baseline until neutrophil recovery following induction chemotherapy (IC) in 97 AML patients. Microbiome characteristics were correlated with clinical outcomes both during and after IC completion.
At the start of IC, higher stool Shannon diversity (hazard ratio [HR], 0.36; 95% confidence interval [CI], .18-.74) and higher relative abundance of Porphyromonadaceae (HR, 0.36; 95% CI, .18-.73) were associated with increased probability of remaining infection-free during neutropenia. A baseline stool Shannon diversity cutoff of <2 had optimal operating characteristics for predicting infectious complications during neutropenia. Although 56 patients received therapy >72 hours with a carbapenem, none of the patients had an infection with an extended spectrum β-lactamase-producing organism. Patients who received carbapenems for >72 hours had significantly lower α-diversity at neutrophil recovery (P = .001) and were approximately 4 times more likely to have infection in the 90 days following neutrophil recovery (HR, 4.55; 95% CI, 1.73-11.93).
Our results suggest that gut microbiome evaluation could assist with infectious risk stratification and that improved targeting of antibiotic administration during IC could decrease subsequent infectious complications in AML patients.Baseline microbiome diversity is a strong independent predictor of infection during acute myeloid leukemia induction chemotherapy (IC) among clinical and microbiome covariates. Higher baseline levels of Porphyromonadaceae appear protective against infection, while carbapenem use is associated with consequences to the microbiome and infection susceptibility post-IC.
大多数研究都集中在移植环境中,探讨微生物组对血液系统恶性肿瘤患者健康的影响。在这里,我们试图评估胃肠道微生物组的预测能力及其与急性髓系白血病(AML)患者感染结局的关系。
对 97 例 AML 患者接受诱导化疗(IC)前至中性粒细胞恢复期间每两周采集的口腔拭子和粪便样本进行 16s rRNA 分析。在 IC 期间和完成后,将微生物组特征与临床结局相关联。
在 IC 开始时,粪便 Shannon 多样性较高(风险比 [HR],0.36;95%置信区间 [CI],.18-.74)和卟啉单胞菌科相对丰度较高(HR,0.36;95%CI,.18-.73)与中性粒细胞减少期间感染无残留的可能性增加相关。基线粪便 Shannon 多样性<2 的截断值可最佳预测中性粒细胞减少期间的感染并发症。尽管 56 例患者接受了>72 小时的碳青霉烯类药物治疗,但没有患者发生产超广谱β-内酰胺酶的病原体感染。在中性粒细胞恢复时,接受碳青霉烯类药物治疗>72 小时的患者α多样性显著降低(P=0.001),且在中性粒细胞恢复后 90 天内感染的可能性约增加 4 倍(HR,4.55;95%CI,1.73-11.93)。
我们的研究结果表明,肠道微生物组评估可协助进行感染风险分层,而在 IC 期间更精准地靶向抗生素治疗可能会降低 AML 患者的后续感染并发症。基线微生物组多样性是 AML 患者 IC 期间感染的一个强有力的独立预测因子,与临床和微生物组协变量相关。较高的基线卟啉单胞菌科水平似乎具有抗感染作用,而碳青霉烯类药物的使用与 IC 后微生物组和感染易感性的变化有关。